NEW YORK ─ IVD industry raw materials supplier Medix Biochemica last week announced it has acquired Germany-based MyPols Biotec, a manufacturer of molecular diagnostics raw materials, for an undisclosed amount.
Espoo, Finland-based Medix said the acquisition broadens its portfolio of molecular diagnostic raw materials, complements its scientific expertise, and strengthens its presence in Western Europe. MyPols will form a significant part of Medix's newly established molecular diagnostics business unit, Medix said.
MyPols offers DNA polymerases, master mixes, DNA polymerase-based assays, and reagents in both liquid and lyophilized format for IVD and research use. The firm tailors DNA polymerases for applications such as PCR, CRISPR, NGS, isothermal amplification, and SNP detection.
The MyPols product portfolio will be available through Medix Biochemica’s global sales network.
"This acquisition … further accelerates Medix Biochemica’s growth in [its] molecular diagnostics reagents business which is a key strategic expansion area for us," Steve Ferguson, CEO of Medix Biochemica, said in a statement.
MyPols technology will enable Medix Biochemica's customers to shorten their assay development time and conduct molecular diagnostic testing from crude samples, he said.
Founded in 2014, MyPols will continue to operate in Konstanz, Germany, and its founders will remain with the business following the acquisition. Ramon Kranaster and Simone Marx will having key operational roles in the MDx business and Andreas Marx will continue as a senior advisor.